EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access

Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry

Anton Håkansson iD, Sasha Koul, Elmir Omerovic iD, Jonas Andersson iD, Stefan James iD, Stefan Agewall iD, Arash Mokhtari iD, Jesper van Der Pals iD, Axel Wester iD, Karolina Szummer iD, Tomas Jernberg iD, David Erlinge und 1 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.034709 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Anton Håkansson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Clinical Sciences Lund University, Skåne University Hospital Lund Sweden. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Registries, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual antiplatelet therapy (DAPT) reduces ischemic events but increases bleeding risk, especially in patients with high bleeding risk (HBR). This study aimed to compare outcomes of abbreviated versus standard DAPT strategies in patients with HBR with acute coronary syndrome undergoing percutaneous coronary intervention. Methods and Results Patients from the SWEDEHEART (Swedish Web‐system for Enhancement and Development of Evidence‐Based Bare in Heart Disease Evaluated According to Recommended Therapies) registry with at least 1 HBR criterion who underwent percutaneous coronary intervention for acute coronary syndrome were identified and included. Patients were divided into 2 groups based on their planned DAPT time at discharge: 12‐month DAPT or an abbreviated DAPT strategy and matched according to their prescribed P2Y12 inhibitor at discharge. The primary outcome assessed was time to net adverse clinical events at 1 year, which encompassed cardiac death, myocardial infarction, ischemic stroke, or clinically significant bleeding. Time to major adverse cardiovascular events and the individual components of net adverse clinical events were considered secondary end points. A total of 4583 patients were included in each group. The most frequently met HBR criteria was age older than 75 years (65.6%) and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy score ≥25 (44.6%) in the standard DAPT group and oral anticoagulant therapy (79.6%) and age 75 years and older (55.2%) in the abbreviated DAPT group. There was no statistically significant difference in net adverse clinical events (12.9% versus 13.1%; hazard ratio [HR], 0.99 [95% CI, 0.88–1.11], P =0.83), major adverse cardiovascular events (8.6% versus 7.9%; HR, 1.08 [95% CI, 0.94–1.25]), or their components between groups. The results were consistent among all of the investigated subgroups.

Conclusions

In patients with HBR undergoing percutaneous coronary intervention due to acute coronary syndrome, abbreviated DAPT was associated with comparable rates of net adverse clinical events and major adverse cardiovascular events to a DAPT duration of 12 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionRegistriesDual Anti-Platelet TherapyHemorrhagePlatelet Aggregation InhibitorsHumansMaleFemaleAgedMiddle AgedTime FactorsSwedenRisk FactorsRisk AssessmentTreatment OutcomeDrug Administration ScheduleAged, 80 and overPurinergic P2Y Receptor Antagonists

Stichwörter der Autor:innen

SWEDEHEARTacute coronary syndromedual antiplatelet therapyhigh bleeding riskpercutaneous coronary intervention

Substanzen

Platelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Clinical Sciences Lund University, Skåne University Hospital Lund Sweden.
  • Department of Cardiology Sahlgrenska University Hospital, Gothenburg University Gothenburg Sweden.
  • Department of Cardiology Umeå University Umeå Sweden.
  • Department of Cardiology Uppsala University Uppsala Sweden.
  • Department of Clinical sciences, Danderyd Hospital Karolinska institutet Stockholm Sweden.
  • Department of Medicine Huddinge, Karolinska Institutet Stockholm Sweden.

ORCID-Profile: Anton Håkansson, Elmir Omerovic, Jonas Andersson, Stefan James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Szummer, Tomas Jernberg, Moman A Mohammad

Zitieren

APA

Håkansson, A., Koul, S., Omerovic, E., Andersson, J., James, S., Agewall, S., Mokhtari, A., van Der Pals, J., Wester, A., Szummer, K., Jernberg, T., Erlinge, D., & Mohammad, M. A. (2024). Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034709

Vancouver

Håkansson A, Koul S, Omerovic E, Andersson J, James S, Agewall S, et al. Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.034709

BibTeX
@article{Hkansson2024,
  author = {Håkansson, Anton and Koul, Sasha and Omerovic, Elmir and Andersson, Jonas and James, Stefan and Agewall, Stefan and Mokhtari, Arash and van Der Pals, Jesper and Wester, Axel and Szummer, Karolina and Jernberg, Tomas and Erlinge, David and Mohammad, Moman A},
  title = {Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.034709}
}
Kostenlos starten →